Compare Dow Jones Industrial Average ETF (DIA) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Enveric Biosciences Inc — how do they compare? Dow Jones Industrial Average ETF trades at $512.56 (market cap $45.20B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Dow Jones Industrial Average ETF is far larger — about 6756.4× Enveric Biosciences Inc's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Enveric Biosciences Inc for 14 Days on average.
| DIA | ENVB | |
|---|---|---|
Market Cap | $45.20B | $6.69M |
Volume | 4,095,368 | 41,141 |
52-Week High | $542.79 | $10.80 |
52-Week Low | $451.37 | $1.27 |
Typical Hold Time | 103 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | -$1.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $511.02, down 0.68% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces selling pressure according to ADX indicators. Recent dividend distributions provide income appeal, though key valuation metrics remain unavailable. Support levels cluster around $506-509 while resistance sits at $512-516.
The ETF faces near-term headwinds from technical weakness and broader market volatility. Dividend payments offer income stability, but lack of fundamental metrics limits valuation assessment. Market sentiment remains cautious amid economic uncertainty and Fed policy concerns.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
